CINJ 040804: (NJ 1108) Phase I/II Study of Ixabepilone in Combination with the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients with Metastatic Breast Cancer.

Trial Profile

CINJ 040804: (NJ 1108) Phase I/II Study of Ixabepilone in Combination with the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients with Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2013

At a glance

  • Drugs Ixabepilone (Primary) ; Hydroxychloroquine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jun 2009 Additional lead investigator (Eleff M) added as reported by New Jersey Cancer Trial Connect record.
    • 25 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect; CINJ040804)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top